More from AHA including SGLT2 inhibitors, blood transfusion after MI; cracks in the armor of Factor XI inhibitors; and renal denervation are the topics John Mandrola, MD, covers in this week’s podcast.

This podcast is intended for healthcare professionals only.

To read a partial transcript or to comment, visit:

https://www.medscape.com/twic

I. DAPA MI

Potential Dapagliflozin Benefit Post-MI Is Not a 'Mandate'

https://www.medscape.com/s/viewarticle/998378

- NEJM Evidence: Dapagliflozin After MI https://evidence.nejm.org/doi/full/10.1056/EVIDoa2300286

II. Blood Transfusion Strategy Post MI

In MI With Anemia, Results May Favor Liberal Transfusion: MINT

https://www.medscape.com/viewarticle/998376

- MINT NEJM -- https://www.nejm.org/doi/full/10.1056/NEJMoa2307983

- REALITY https://jamanetwork.com/journals/jama/fullarticle/2776201

- PROTECTED TAVR - https://www.nejm.org/doi/full/10.1056/NEJMoa2204961

III. FACTOR XI

Impressive Bleeding Profile With Factor XI Inhibitor in AF: AZALEA

https://www.medscape.com/viewarticle/998418

Asundexian Phase 3 AF Study Halted for Lack of Efficacy

https://www.medscape.com/viewarticle/998665

- Abelacimab for VTE https://www.nejm.org/doi/full/10.1056/NEJMoa2105872

IV. Renal Denervation

FDA Panel Split on Efficacy of Spyral Renal Denervation

https://www.medscape.com/viewarticle/995800

FDA OKs Symplicity Renal Denervation System for Hypertension

https://www.medscape.com/viewarticle/998664

- SPYRAL HTN OFF MED  -- https://doi.org/10.1016/S0140-6736(20)30554-7

- SPRYAL HTN On Meds (Pilot Lancet 2018 ) https://doi.org/10.1016/S0140-6736(18)30951-6

- SPRYAL HTN ON Meds (Expansion Pilot) https://doi.org/10.1016/j.jacc.2023.08.045

You may also like:

Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine

https://www.medscape.com/features/public/machine

The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington

Questions or feedback, please contact news@medscape.net